Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Huawei LinSchool of Chemistry and Pharmaceutical Engineering, Shandong First Medical University, Shandong Academy of Medical Sciences Taian 271016 Shandong P. R. China yuanchunhao2017@163.com geyanqing2016@126.com.
Huimin YangSchool of Chemistry and Pharmaceutical Engineering, Shandong First Medical University, Shandong Academy of Medical Sciences Taian 271016 Shandong P. R. China yuanchunhao2017@163.com geyanqing2016@126.com.
Qi GongSchool of Chemistry and Pharmaceutical Engineering, Shandong First Medical University, Shandong Academy of Medical Sciences Taian 271016 Shandong P. R. China yuanchunhao2017@163.com geyanqing2016@126.com.
Shan LuoSchool of Chemistry and Pharmaceutical Engineering, Shandong First Medical University, Shandong Academy of Medical Sciences Taian 271016 Shandong P. R. China yuanchunhao2017@163.com geyanqing2016@126.com.
Jing GuSchool of Chemistry and Pharmaceutical Engineering, Shandong First Medical University, Shandong Academy of Medical Sciences Taian 271016 Shandong P. R. China yuanchunhao2017@163.com geyanqing2016@126.com.
Xiaoqun CaoSchool of Chemistry and Pharmaceutical Engineering, Shandong First Medical University, Shandong Academy of Medical Sciences Taian 271016 Shandong P. R. China yuanchunhao2017@163.com geyanqing2016@126.com.
Biming MaoInstitute of Materia Medica, Shandong First Medical University, Shandong Academy of Medical Sciences Jinan 250117 Shandong P. R. China maobiming@sdfmu.edu.cn.
Yanqing GeSchool of Chemistry and Pharmaceutical Engineering, Shandong First Medical University, Shandong Academy of Medical Sciences Taian 271016 Shandong P. R. China yuanchunhao2017@163.com geyanqing2016@126.com.ORCID https://orcid.org/0000-0001-6464-0881
Chunhao YuanSchool of Chemistry and Pharmaceutical Engineering, Shandong First Medical University, Shandong Academy of Medical Sciences Taian 271016 Shandong P. R. China yuanchunhao2017@163.com geyanqing2016@126.com.ORCID https://orcid.org/0000-0003-2155-1779
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
The metal-free DBU catalyzed [3+2] cycloaddition of 3-homoacyl coumarins with cyclic 1-azadienes proceeded smoothly to furnish the corresponding highly functionalized cyclopentane-fused coumarins with excellent diastereoselectivity and complete chemoselectivity and in good yields under mild conditions.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Construction of cyclopentane-fused coumarins · full record | OpenQuestion